Evaluation of Serum Annexin A1 Values in Patients with Inflammatory Bowel Diseases

Objective: Annexin A1(AnxA1) is an anti-inflammatory mediator. In the current study,we aimed to evaluate whether or not serum Annexin A1 levels of inflammatory boweldiseases (IBDs) patients relate to the clinical and laboratory traits of IBDs.
Methods: This case-control study included 67 ulcerative colitis (UC) patients (47 males and 20 females), 53 Crohn's disease (CD) patients (37 males and 16 females) and 60 healthy controls (36 males and 24 females). The Mayo Clinical scoring system (MCS) was used for UC and the histological activity index (HAI) was determined by Truelove and Richards method. The Crohn's disease activity index (CDAI) was used for CD patients. Montreal classification was used for the localization of IBDs.
Results: The mean serum AnxA1 concentrations were not statistically significant in UC, CD and the control groups (26.36 +/- 17.30 ng/ml vs 22.98 +/- 12.74 vs 24.45 +/- 12.18 ng/ml respectively, p=0.404). The MCS, HAI of UC patients negatively correlated with the serum AnxA1 values (rho=-0.616, p<0.001 vs rho=-0.778, p<0.001 respectively). UC patients with limited disease had higher values than those with extensive disease (19.5 (IQR:14.5-47.8) ng/ml vs.13.4 (IQR:10.8-18.4) ng/ml respectively, p=0.002). In CD patients, CDAI values negatively correlated to the serum AnxA1 values (rho=-0.770, p<0.001).
Conclusions: Serum AnxA1 values might be an auxiliary biomarker for the disease activity in patients with IBDs.